Genzyme, Sanofi Take Aim At Generic Cancer Drug

Law360, New York (August 30, 2013, 6:03 PM EDT) -- Drugmakers Genzyme and Sanofi-Aventis sued three pharmaceutical companies Friday in Delaware federal court, claiming that the companies’ generic drugs will violate Genzyme’s patents for the cancer treatment drug Mobozil.

The complaints, filed in the U.S. District Court for the District of Delaware, allege that Sandoz, Inc., Teva Pharmaceuticals USA, Inc. and India-based Dr. Reddy's Laboratories will infringe Genzyme’s patents if they are allowed to market Plerixafor Injection 20mg/mL, a proposed generic version of Genzyme’s Mobozil. If not enjoined, the defendants' infringement will "substantially and irreparably" harm...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.